Drucker NA, Colan SD, Lewis AB, Beiser AS, Wessel DL, Takahashi M, et al (1994). Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation, 89:252–7. Ontario Regional Blood Coordinating Network (2016). Ontario Intravenous Immune Globulin (IVIG) Utilization Management Guidelines, Version 3.0. [online]. Available at: http://transfusionontario.org/en/download/ontario-intravenous-immune-globulin-IVIg-utilization-management-guidelines-2/. Robinson J, Hartling L, Vandermeer B and Klassen TP (2005). Intravenous immunoglobulin for presumed myocarditis in children and adults (Cochrane Review). Cochrane Database of Systematic Reviews 2005, Issue 1. (Updated May 2015) UK Department of Health (2011) Clinical Guidelines for Immunoglobulin Use: Second Edition Update. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/216671/dh_131107.pdf UK Department of Health (2011) Clinical Guidelines for Immunoglobulin Use: Second Edition Update: Summary Poster. Available at: POTENTIAL OPERATIONAL IMPACT Prescribers will need to be advised that Ig therapy will not be available for this condition to enable them to be prepared to manage patients without Ig therapy. Following public consultation and the subsequent endorsement by governments, specific communication with relevant prescribers is planned. As Ig treatment for this condition has historically been short term therapy, it is anticipated that a very small number of patients is likely to be being treated at the time of implementation of this change. To support doctors to provide optimal patient management, advice will be provided to prescribers well prior to the date of implementation of this change. POTENTIAL IMPACT ON PATIENTS, DEMAND AND EXPENDITURE Potential impact on patients: It is recommended that this condition no longer be supported for funding under the national blood arrangements because alternative therapies have been demonstrated to be effective in managing the condition, are available and are being used in Australia. There is very little evidence to support any beneficial effect from Ig therapy and recent scientific reviews have suggested that Ig therapy should not be used as routine treatment in children or adults with this condition.
Drucker NA, Colan SD, Lewis AB, Beiser AS, Wessel DL, Takahashi M, et al (1994). Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation, 89:252–7. Ontario Regional Blood Coordinating Network (2016). Ontario Intravenous Immune Globulin (IVIG) Utilization Management Guidelines, Version 3.0. [online]. Available at: http://transfusionontario.org/en/download/ontario-intravenous-immune-globulin-IVIg-utilization-management-guidelines-2/. Robinson J, Hartling L, Vandermeer B and Klassen TP (2005). Intravenous immunoglobulin for presumed myocarditis in children and adults (Cochrane Review). Cochrane Database of Systematic Reviews 2005, Issue 1. (Updated May 2015) UK Department of Health (2011) Clinical Guidelines for Immunoglobulin Use: Second Edition Update. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/216671/dh_131107.pdf UK Department of Health (2011) Clinical Guidelines for Immunoglobulin Use: Second Edition Update: Summary Poster. Available at: POTENTIAL OPERATIONAL IMPACT Prescribers will need to be advised that Ig therapy will not be available for this condition to enable them to be prepared to manage patients without Ig therapy. Following public consultation and the subsequent endorsement by governments, specific communication with relevant prescribers is planned. As Ig treatment for this condition has historically been short term therapy, it is anticipated that a very small number of patients is likely to be being treated at the time of implementation of this change. To support doctors to provide optimal patient management, advice will be provided to prescribers well prior to the date of implementation of this change. POTENTIAL IMPACT ON PATIENTS, DEMAND AND EXPENDITURE Potential impact on patients: It is recommended that this condition no longer be supported for funding under the national blood arrangements because alternative therapies have been demonstrated to be effective in managing the condition, are available and are being used in Australia. There is very little evidence to support any beneficial effect from Ig therapy and recent scientific reviews have suggested that Ig therapy should not be used as routine treatment in children or adults with this condition.
Myocarditis-in-children2017.docx